Raiffeisen Bank International AG Purchases Shares of 38,894 Pfizer Inc. (NYSE:PFE)

Raiffeisen Bank International AG bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 38,894 shares of the biopharmaceutical company's stock, valued at approximately $1,027,000.

Other hedge funds have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $28,000. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

PFE opened at $22.83 on Friday. The company has a 50-day moving average of $23.65 and a 200-day moving average of $25.36. The company has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.82 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.